STOCK TITAN
  1. Home
  2. News
  3. TBPH

Theravance Biopharma Inc - TBPH STOCK NEWS

IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
conferences earnings
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
conferences
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
conferences earnings
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
clinical trial
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
conferences earnings
IMPACT
SENTIMENT
TBPH : Nasdaq
Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma’s Board of Directors
management
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
management
IMPACT
SENTIMENT
TBPH : Nasdaq
Theravance Biopharma to Participate in an Upcoming Investor Conference
conferences
Stock TBPH logo
Theravance Biopharma Inc
Nasdaq:TBPH

TBPH Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing

About TBPH

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.